Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Simcere Announces Third Drug Development Partnership with BMS

publication date: Jun 14, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharma has formed a third drug development collaboration with Bristol-Myers Squibb. For the first time, the project involves a biologic molecule: a subcutaneous formulation of Orencia®, a treatment for rheumatoid arthritis. Orencia is already approved for use in the US, Europe and Japan. Simcere will be responsible for obtaining China approval of the drug. Then, the two companies will co-market Orencia in China, sharing profits and losses. More details....

Stock Symbols: (NYSE: SCR) (NYSE: BMY)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...